Business Wire

Cirium Enhances Industry-Leading On-Time Performance Advisory Board with Three Esteemed Aviation Leaders

Share

Cirium, the world’s most trusted source of aviation analytics, has appointed three prominent aviation experts to its Airline and Airport On-Time Performance Advisory Board. The move underscores Cirium’s commitment to maintaining its position as the global gold standard for airline and airport performance analytics.

As the first and only company to establish an On-Time Performance Advisory Board, Cirium ensures an unbiased, data-driven view of operational excellence. The latest appointments—Eamonn Brennan, Scott McCartney, and Alex de Gunten—bring over 75 years of combined experience, enhancing the board’s mission to uphold Cirium’s reputation as the industry benchmark.

Jeremy Bowen, Cirium CEO, said “Adding Eamonn, Scott, and Alex to our Advisory Board is a confirmation of our unwavering commitment to operational reliability and excellence. Their unique perspectives, spanning safety, operations, performance, journalism, and global airline strategy, will amplify our ability to provide independent, accurate data and insights. Together, we are shaping the future of aviation performance analytics for our partners worldwide.”

Meet the New Advisory Board Members

Eamonn Brennan

Eamonn Brennan joins the board with a distinguished record of leadership in aviation safety, performance, and airspace management. Currently serving as a Non-Executive Director at Ryanair, Brennan was the Director General of EUROCONTROL from 2018 to 2022, steering the organization through pivotal challenges such as the record-setting summer of 2019 and the COVID-19 pandemic. During his tenure, he ensured the resilience of the European Air Traffic Network, overseeing 11 million annual flights.

Previously, Brennan served as Chief Executive of the Irish Aviation Authority (2002–2017), achieving significant advancements in safety, cost efficiency, and airspace management. A pioneer in privatization efforts, he led the Airline Group’s successful bid for the UK’s first partial privatization of an Air Navigation Service Provider. Brennan has also held key leadership roles, including Chairman of CANSO Global and the COOPANS Alliance.

Scott McCartney

Scott McCartney, a renowned aviation journalist and business consultant, brings decades of expertise in analyzing and reporting on industry trends. For over 20 years, he penned The Middle Seat, The Wall Street Journal’s celebrated travel column, where he launched its highly regarded airline performance rankings.

McCartney was part of the Pulitzer Prize-winning team of journalists for its coverage of 9/11 and the author of four acclaimed books. His numerous accolades include the George Polk Award and SABEW’s “Best in Business” honors. Currently, he serves as an adjunct professor at Duke University and hosts Airlines Confidential, a globally recognized business podcast. He also leads Middle Seat LLC, a consultancy specializing in media training and aviation research.

Alex De Gunten

A seasoned aviation executive with a global perspective, Alex de Gunten joins the board with over 20 years of strategic leadership experience. As Business Development Officer at HEICO Aerospace, he has played a pivotal role in advancing aerospace innovation.

Previously, de Gunten served as Executive Director of the Latin American and Caribbean Air Transport Association (ALTA), fostering collaboration among regional airlines to address industry challenges. He also drove international expansion efforts as Vice President at LAN Chile and Canadian Airlines International. A multilingual leader fluent in English, Spanish, and French, de Gunten is a sought-after speaker and advisor to organizations such as ALTA and TravelX.

Strengthening Cirium’s Advisory Board

Chaired by Cirium CEO Jeremy Bowen, the board now comprises a powerhouse of aviation expertise, including former airline executive Willy Boulter, ACI World Director General Luis Felipe de Oliveira, and Atmosphere Research Group President Henry Harteveldt.

Board member, Mike Malik Cirium’s Chief Marketing Officer also serves as On-Time Committee Chairperson, and Lydia Webb, Cirium’s Marketing Director – Americas & Strategic Programs, is the Board Secretary.

This strengthened board equips Cirium to continue delivering unmatched insights and analytics to airlines, airports, and other stakeholders in the aviation industry.

About Cirium

Cirium® is the world’s most trusted source of aviation analytics. The company delivers powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities with the clarity and intelligence they need to optimize their operations, make informed decisions, and accelerate revenue growth.

Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium® on LinkedIn or visit cirium.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204844057/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye